Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuzatrelvir versus placebo in high-risk non-hospitalized patients with COVID-19
2024-517727-39-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ibuzatrelvir with Placebo (2 arms). Primary endpoint: COVID-19-related emergency department visit, hospitalization, or death through Day 28. Planned start Jul 2025; status: authorised.
02
Drugs
ibuzatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-517727-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517727-39-00.